Related Experiment Video

Updated: May 17, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer

Xuesong Chen1, Qingwei Meng, Yanbin Zhao

  • 1Department of Internal Medical Oncology, The Third Affiliated Hospital of Harbin Medical University, Harbin 150040, Heilongjiang Province, China.

Cancer Letters
|October 25, 2012
PubMed

Insights

Angiotensin II type 1 receptor (AT1R) antagonists show potential in breast cancer treatment. These drugs may inhibit tumor growth and angiogenesis by targeting the angiotensin II pathway.

Area of Science:

  • Oncology
  • Pharmacology
  • Cardiovascular Research

Background:

  • The angiotensin II type 1 receptor (AT1R) plays a role in tumor progression, including invasion, migration, metastasis, and angiogenesis.
  • Understanding the role of AT1R in breast cancer is crucial for developing novel therapeutic strategies.

Purpose of the Study:

  • To investigate the potential antitumor effects of AT1R antagonists in breast cancer.
  • To explore the impact of AT1R blockade on tumor growth, angiogenesis, and related molecular pathways.

Main Methods:

  • In vitro studies using MCF-7 breast cancer cells treated with angiotensin II and AT1R antagonists (losartan).
  • In vivo studies using mice bearing MCF-7 xenografts treated with candesartan.
  • Analysis of AT1R and vascular endothelial growth factor A (VEGF-A) expression in patient tumor samples and correlation with microvascular density.

Main Results:

  • Angiotensin II promoted proliferation and upregulated VEGF-A in MCF-7 cells.
  • Losartan and candesartan downregulated VEGF-A expression.
  • Candesartan inhibited tumor growth and angiogenesis in a mouse model.
  • AT1R and VEGF-A expression positively correlated with microvascular density in breast cancer patients.

Conclusions:

  • AT1R antagonists demonstrate antitumor effects in preclinical models of breast cancer.
  • Inhibition of the angiotensin II pathway via AT1R antagonists may suppress breast cancer growth and angiogenesis.
  • Targeting AT1R represents a potential therapeutic strategy for breast cancer management.

More Related Videos

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...